Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial

Autor: Jo Hardy, Christina Baggott, James Fingleton, Helen K Reddel, Robert J Hancox, Matire Harwood, Andrew Corin, Jenny Sparks, Daniela Hall, Doñah Sabbagh, Saras Mane, Alexandra Vohlidkova, John Martindale, Mathew Williams, Philippa Shirtcliffe, Mark Holliday, Mark Weatherall, Richard Beasley, Liz Dronfield, Colin Helm, Tracy Paterson, Bhuwan Poudel, Malcolm Dyer, Christine Jasinski, Davitt Sheahan, Pamela Sheahan, Nick Gailer, Jan Van Zuilen, Andy Basa, Christine Devereaux, Karin Egan, Sneha Haughey, Rodney Marks, Dirk Venter, Hank Zhang, Karen Trevithick, Mike Williams, Philippa Williams, Irene Braithwaite, Alexandra Eathorne, Stefan Ebmeier, Claire Houghton, Karen Oldfield, Janine Pilcher, Suzanne Snively, Patrick Collins, Summer Hassan, Annika Lam, Claudette Lionnet, Barney Montgomery, Liz Smaill, Stella Moon, Dean Quinn, Elena Bayly-McCredie, Chris Millar-Coote, Dean Millar-Coote, Jim Reid, Anna Samuel, Nicola Burton, Tina Mullard, Tyronne Tranquilino, Edward Watson, Jill Bell, Rachel Harris, John Richmond, Sue Smith, Brent Krivan, Cheryl Robertson, Sue Glensor, Dermot O'Connor, Anne-Christine Porrachia

Publikováno v: The Lancet. 394:919-928

Summary Background In adults with mild asthma, a combination of an inhaled corticosteroid with a fast-onset long-acting β-agonist (LABA) used as reliever monotherapy reduces severe exacerbations compared with short-acting β-agonist (SABA) reliever

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c02f5182bdf8a5417cf670e91b9210b1
https://doi.org/10.1016/s0140-6736(19)31948-8